Valvular & structural heart diseaseCohort study
Association between lipoprotein(a), LPA genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events
- Prospective cohort study
Authors' conclusion
An LPA GRS can explain 45% of variation in Lp(a) levels, and both Lp(a) and the GRS are associated with CAVD. An elevated GRS is associated with future cardiac events in a secondary risk setting, but, if the CAD status is known, it does not provide additional prognostic information.
Study context
- Population
- Patients undergoing coronary angiography, January 2012 to May 2013analysable
- Participants
- 752 patients
- Exposure
- Measured Lp and LPA genetic risk score vs calcific aortic valve disease (CAVD) and MACE
- Outcome
- CAVD at baseline and MACE
- Follow-up
- 7-year follow-up
Main finding
As reported in the abstract
Odds ratio (95% CI)P value
Lp(a)CAVD, per 10-unit increase, adjusted for cardiac risk factors and CAD
1.039(1.022–1.057)
P < 0.001GRSCAVD, per 10-unit increase, adjusted for cardiac risk factors and CAD
1.054(1.024–1.086)
P < 0.001GRS >54MACE, with CAD classification in the model
1.333(0.927–1.912)
P = 0.12Per 10-unit increase, as printed
Observational data: associations, not effects.
Further findings
Variation in Lp(a) explained by genetic risk score (GRS)
- GRS explained variation in Lp(a)
- 45%
- Lp(a) measured in 446; GRS calculable in 703
Original publication
Association between lipoprotein(a), LPA genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events. Eur J Prev Cardiol. Published 9 April 2024. doi:10.1093/eurjpc/zwae100
Summarised from the published abstract; every number is checked against it